Literature DB >> 8934794

Contemporary issues in mast cell biology.

G Nilsson1, D D Metcalfe.   

Abstract

Mast cells are the principal initial effector cells in the modulation of allergic inflammation. They are now known to arise from CD34+ pluripotential stem cells, circulate through the blood as CD34+, Fc epsilon RI-, Kit+ committed but undifferentiated cells, and migrate into tissues where they mature in the presence of Kit-ligand (stem cell factor) and other locally produced cytokines. Mast cells undergo programmed cell death (apoptosis) when stem cell factor is not available. Mast cells adhere to specific connective tissue components such as fibronectin and laminin. This interaction localizes mast cells to specific sites while altering their biologic responsiveness. Mast cells, when activated through Fc epsilon RI, release and generate a wide variety of cytokines including IL-4 and IL-5. This information provides new insights on how allergic reactions may be modified by developing strategies to effect mast cell viability, survival and localization; and the production of inflammatory mediators.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8934794     DOI: 10.2500/108854196778645074

Source DB:  PubMed          Journal:  Allergy Asthma Proc        ISSN: 1088-5412            Impact factor:   2.587


  4 in total

1.  Paediatric mastocytosis.

Authors:  M C Carter; D D Metcalfe
Journal:  Arch Dis Child       Date:  2002-05       Impact factor: 3.791

2.  Demonstration of mast cell chemotactic activity in synovial fluid from rheumatoid patients.

Authors:  N Olsson; A K Ulfgren; G Nilsson
Journal:  Ann Rheum Dis       Date:  2001-03       Impact factor: 19.103

3.  Functional and phenotypic studies of two variants of a human mast cell line with a distinct set of mutations in the c-kit proto-oncogene.

Authors:  Magnus Sundström; Harissios Vliagoftis; Peter Karlberg; Joseph H Butterfield; Kenneth Nilsson; Dean D Metcalfe; Gunnar Nilsson
Journal:  Immunology       Date:  2003-01       Impact factor: 7.397

4.  Human mast cells decrease SLPI levels in type II - like alveolar cell model, in vitro.

Authors:  Camilla Hollander; Max Nyström; Sabina Janciauskiene; Ulla Westin
Journal:  Cancer Cell Int       Date:  2003-08-20       Impact factor: 5.722

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.